8-K: Neumora Therapeutics Announces Leadership Shakeup: Berns Takes CEO Reins, Pinto Promoted to President

Neumora Therapeutics announces a leadership transition with Paul L. Berns stepping in as CEO and Joshua Pinto becoming President, effective February 14, 2025.

Summary

• Neumora Therapeutics announced a leadership transition effective February 14, 2025.
• Paul L. Berns, the company's Co-Founder and Executive Chairman, will become Chief Executive Officer and Chairman of the Board.
• Henry Gosebruch will depart from his roles as President, Chief Executive Officer, and Board member.
• Joshua Pinto, Ph.D., will transition from Chief Financial Officer to President, with an increased annual base salary of $645,000 and eligibility for a 60% annual bonus.
• Dr. Pinto will also receive a one-time signing bonus of $970,000, subject to clawback if he leaves before August 13, 2026.
• Dr. Pinto was granted an option to purchase 3,000,000 shares of Company common stock that vests over four years.
• Bill Aurora, Pharm.D., will become Chief Operating and Development Officer, with an increased annual base salary of $545,000 and eligibility for a 50% annual bonus.
• Dr. Aurora will receive a one-time signing bonus of $860,000, subject to clawback if he leaves before August 13, 2026.
• Dr. Aurora was granted an option to purchase 1,000,000 shares of Company common stock that vests over four years.
• Michael Milligan will serve as Chief Financial Officer in addition to his current role as principal accounting officer, with an increased annual base salary of $450,000 and eligibility for a 40% annual bonus.
• Jason Duncan will serve as Chief Legal and Administrative Officer.
• Carol Suh will transition from Chief Operating Officer to Chief Strategy Officer.
• Kaya Pai Panandiker will depart from her role as Chief Commercial Officer.
• The Board approved an option repricing of outstanding stock options held by members of the Board, certain employees and other service providers, excluding Mr. Gosebruch, subject to stockholder approval.
• Neumora will host a conference call on March 3, 2025, to report its fourth quarter and full year 2024 financial results and provide a business update.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the leadership changes and pipeline advancements, but tempered by the departure of key personnel and the risks inherent in drug development.

Positives

• Joshua Pinto's promotion to President includes a salary increase, bonus eligibility, and a signing bonus.
• Bill Aurora's promotion to Chief Operating and Development Officer includes a salary increase, bonus eligibility, and a signing bonus.
• Michael Milligan's promotion to Chief Financial Officer includes a salary increase and bonus eligibility.
• The option repricing aims to restore incentive for service providers to remain with the company.
• Neumora has a pipeline of seven programs, with clinical data readouts expected in 2025.

Negatives

• Henry Gosebruch is leaving the company.
• Kaya Pai Panandiker is departing from her role as Chief Commercial Officer.
• The option repricing is contingent on stockholder approval.

Risks

• The forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially.
• Clinical drug development is inherently uncertain and involves a lengthy regulatory approval process.
• The company relies on third parties, including clinical research organizations.
• Therapeutic candidates may have serious or undesirable side effects.
• The company's ability to utilize and protect its intellectual property rights is crucial.
• The company needs sufficient capital resources to fund operations.

Future Outlook

Neumora expects clinical data readouts from all three of its clinical-stage programs in 2025 and aims to reshape the treatment of brain diseases.

Management Comments

• Paul L. Berns stated that Neumora is poised to reach its potential, working to maximize shareholder value and make a difference for people living with brain diseases.
• Joshua Pinto stated that Neumora is in a strong position, advancing studies in some of the most prevalent brain diseases with multiple near-term clinical inflection points.

Industry Context

The announcement highlights the ongoing competition in the biopharmaceutical industry, particularly in the neuroscience space, with companies vying to develop novel therapies for brain diseases. Leadership changes and pipeline advancements are common occurrences as companies strive to achieve their goals.

Comparison to Industry Standards

• Executive compensation packages, including base salaries, bonuses, and stock options, are generally in line with industry standards for biopharmaceutical companies of similar size and stage.
• The focus on clinical data readouts and pipeline development is consistent with the priorities of other clinical-stage biopharmaceutical companies, such as Biogen, Eli Lilly, and Pfizer, which are also heavily invested in neuroscience research and development.
• The option repricing is a tool sometimes used by companies to re-incentivize employees when the stock price has declined, similar to actions taken by other companies in the biotech sector facing market volatility.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders may be impacted by the leadership changes and the potential for increased shareholder value.
• Employees may be impacted by the leadership changes and the option repricing.
• Patients may benefit from the company's efforts to develop novel therapies for brain diseases.

Next Steps

• Neumora will file the Employment Agreements as exhibits to its Annual Report on Form 10-K for the year ended December 31, 2024.
• The company will seek stockholder approval for the option repricing.
• Neumora will host a conference call on March 3, 2025, to report its fourth quarter and full year 2024 financial results and provide a business update.
• The company will continue to advance its clinical-stage programs and expects clinical data readouts in 2025.

Key Dates